Hypertension as cause of end-stage renal disease: Lessons from international registries  by Valderrábano, Fernando et al.
HYPERTENSION AND CHRONIC RENAL FAILURE
Hypertension as cause of end-stage renal disease: Lessons from
international registries
FERNANDO VALDERRA´BANO, FRANCISCO GO´MEZ-CAMPDERA´, and ELIZABETH H.P. JONES
Servicio de Nefrologı´a. Hospital General Universitario “Gregorio Maran˜o´n,” Madrid, Spain, and ERA-EDTA Registry, London,
England, United Kingdom
Hypertension as cause of end-stage renal disease: Lessons from
international registries. The incidence of hypertension as cause of
ESRD has doubled in the ERA-EDTA Registry in the past two
decades, going from 7 to 13%. It is very possible that this is not a
real increase in the incidence of hypertension as cause of ESRD,
but rather a consequence of greater acceptance of older patients,
a phenomenon that has simultaneously occurred. There are
geographic differences in the incidence of hypertension as cause
of ESRD, from 6% in Japan to 28.5% in the U.S., and 13% in
Europe. With the present data, it is impossible to know if these
differences are real. The diagnostic criteria used are not uniform
and a consensus would be necessary to establish uniform diagnos-
tic criteria for nephrosclerosis or ischemic nephropathy. The
percentage of patients starting renal replacement therapy (RRT)
with unknown primary renal disease is very different in the U.S.
and Europe. This could be a critical factor in explaining these
differences. Survival of patients at 5 and 10 years with renal
vascular disease did not improve from 1977 to 1989. The same
occurs with survival of patients with standard primary renal
disease, although this is better than that of patients with renal
vascular disease. To interpret this lack of improvement in survival
of patients over a decade, we must take into account that at the
same time there has been a significant increase in the age of
patients starting RRT. Therefore, when the population of pa-
titents of under 55 is analyzed, there is evidence that those starting
treatment in the 80’s have much better survival than those starting
in the 70’s. However, survival of patients with renal vascular
disease continues to be poorer than that of patients with standard
primary renal disease. This lower survival of patients with renal
vascular disease seems to be related to higher cardiac mortality,
which is in alignment with the diagnosis of hypertension as cause
of renal failure.
In the past two decades, there have been significant
qualitative changes in the profile of patients starting renal
replacement therapy (RRT). The mean age of new patients
has increased considerably, such that in different registries
in the 90s, a mean and a median age of over 60 can be
observed. This change has occurred in parallel to a change
in the proportion of the different primary renal diseases
causing ESRD. The percentual decrease in some nephrop-
athies, basically glomerulonephritis, is striking, as opposed
to the increase in the proportion of patients in whom
diabetes and hypertension are the causes of ESRD. It is
significant to note that in the USA, 37.4% of new patients
are diabetic [1], in Europe this percentage is roughly half
[2], whereas Japan [3] comes close to the USA numbers. In
the case of hypertension, the situation is similar. From 1977
to 1992 in Europe, the proportion of patients starting
dialysis as a consequence of hypertension has tripled over
the last years [2].
RENAL VASCULAR DISEASE AS A CAUSE OF END-
STAGE RENAL DISEASE
Data on ESRD consecutive to hypertension are collected
in very different ways in the different international regis-
tries. The USRDS typifies hypertension and renal artery
stenosis as causes of renal failure, but the ERA-EDTA
Registry has three codes under which renal failure consec-
utive to hypertension has been reported over the past years
(70, 71, and 72). Code 70 qualifies nonspecific type renal
vascular disease, code 71 refers to renal vascular disease
due to malignant hypertension, and 72 to renal vascular
disease due to hypertension. Other vascular nephropathies
and vasculitis appear under different codes.
In the Japanese Registry, the only code included refer-
ring to hypertension is nephrosclerosis [3].
INCIDENCE AND PREVALENCE OF RENAL
VASCULAR DISEASE IN PATIENTS ON RRT FROM
1976 TO 1995
Table 1 shows the percentage of patients diagnosed with
renal vascular disease (codes 70 to 72) in the ERA-EDTA
Registry starting RRT in 1977, 1981, 1985, 1989, 1993 and
1995. In 1977 approximately 7% of the patients starting
RRT were diagnosed with renal vascular disease, while this
percentage has progressively increased in more recent
years, reaching nearly 13% in 1995. When the patients are
divided according to age groups, in those under 25 the
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percentages are very low. There is a slight increase in the
proportion of patients with renal vascular disease, which
does not exceed 3% in 1995. In the 25 to 44 age group there
is practically no variation from 1977 to 1995 (ranging
between 5 to 6%). The variations are also very slight in the
45 to 64 age group, but the most outstanding finding is in
patients over 65, who show a considerable increase, nearly
doubled, from 10% in 1977 to 18% in 1995.
When this same data are analyzed according to gender
(Tables 2 and 3), the proportion of males starting RRT
whose diagnosis of primary renal disease is renal vascular
disease is higher than that of females (Fig. 1). In 1995, 14%
of the males starting RRT did so as a consequence of renal
vascular disease, as compared to 10% of females. These
differences are particularly marked in the group of patients
over 65. Although females show a considerable increase
from 8% in 1977 to over 15% in 1995, the increase in males
varies between 12% in 1977 and 22% in 1995.
When the incidence of renal vascular disease in the
ERA-EDTA Registry is compared to that of other conti-
nental registries, it is significant that the USRDS shows
hypertension (including renal artery stenosis) as the cause
of ESRD in 28.5% of the patients starting RRT between
1991 and 1995 [1], which is double the figure of 13%
observed in the ERA-EDTA Registry in 1995. In Spain,
renal vascular disease appears as cause of renal failure in
15% of the patients starting treatment in 1995. It is
interesting to note that the diagnosis of nephrosclerosis
appears in the Japanese Registry in only 6.2% of the
patients starting RRT in 1993 (Fig. 2) [3].
With the progressive increase in age of new patients
starting RRT that was 38% of the new patients in the
ERA-EDTA Registry being over 65 in 1992 [2] in mind, we
have analyzed the incidence of renal vascular disease as a
cause of ESRD in aged patients in other registries. As
Table 1. Total number of patients starting renal replacement therapy
(T) and patients diagnosed with renal vascular disease (RVD)
Age
Total0–24 25–44 45–64 .65
1977
T 1475 4103 5234 1133 11945
RVD 26 232 416 115 789
% 1.76 5.65 7.94 10.1 6.6
1981
T 1989 5307 8225 2844 18365
RVD 34 287 760 307 1388
% 1.7 5.4 9.24 10.7 7.55
1985
T 2249 6035 11192 5308 24784
RVD 40 308 1020 734 2102
% 1.77 5.1 9.11 13.82 8.48
1989
T 2529 7033 13172 8755 31494
RVD 35 361 1267 1362 3025
% 1.38 5.13 9.61 15.5 9.6
1993
T 1769 5330 10737 10658 28494
RVD 48 280 1083 1963 3374
% 2.71 5.25 10 18.4 11.8
1995
T 422 1178 2503 2781 6884
RVD 14 66 248 524 870
% 3.31 5.6 9.9 18.8 12.6
Data are from the ERA-EDTA Registry.
Table 2. Total number of male patients starting renal replacement
therapy (T) and diagnosed with renal vascular disease (RVD)
Age
Total0–24 25–44 45–64 .65
1977
T 852 2570 2992 670 7084
RVD 14 162 301 77 554
% 1.64 6.3 10 11.4 7.8
1981
T 1169 3262 4748 1638 10817
RVD 21 213 531 198 963
% 1.79 6.52 11.1 12 8.9
1985
T 1320 3746 6519 2838 14423
RVD 16 212 721 472 1421
% 1.21 5.65 11 16.6 9.85
1989
T 1442 4393 7922 4836 18593
RVD 21 258 910 888 2077
% 1.45 5.87 11.4 18.3 11.1
1993
T 1069 3384 6593 6002 17048
RVD 33 184 771 1303 2291
% 3 5.43 11.6 21.7 13.4
1995
T 260 728 1469 1579 4036
RVD 8 43 175 340 566
% 3 5.9 11.9 21.5 13.9
Data are from the ERA EDTA Registry.
Table 3. Total number of female patients starting renal replacement
therapy (T) and diagnosed with renal vascular disease (RVD)
Age
Total0–24 25–44 45–64 .65
1977
T 623 1533 2242 463 4861
RVD 12 70 115 38 235
% 1.92 4.56 5.12 8.2 4.83
1981
T 820 2045 3477 1206 7548
RVD 13 74 229 109 425
% 1.58 3.61 6.58 9 5.63
1985
T 929 2289 4673 2470 10361
RVD 24 96 299 262 681
% 2.58 4.19 6.39 10.6 6.57
1989
T 1087 2640 5250 3919 12896
RVD 14 103 357 474 948
% 1.28 3.9 6.8 12 7.35
1993
T 700 1946 4144 4656 11446
RVD 15 96 312 660 1083
% 2.14 4.93 7.52 14.1 9.46
1995
T 162 450 1034 1202 2848
RVD 6 23 73 184 286
% 3.7 5.1 7 15.3 10
Data are from the ERA EDTA Registry.
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mentioned earlier, in 1995 in the ERA-EDTA Registry,
22% of males over 65 who started RRT did so as a
consequence of renal vascular disease (25% in Spain that
same year). However, the USRDS shows that 37.6% of all
patients of both sexes over 65 started RRT as a conse-
quence of renal vascular disease [1].
In analyzing the possible reasons for these differences
between Europe, the U.S. and Japan, it is crucial to know
what criteria were used in making diagnosis of primary
renal disease. One important fact is that the percentage of
patients starting RRT in whom the diagnosis of primary
renal disease is unknown in the USRDS was 4.4% for
patients starting between 1991 and 1995 [1], while in the
ERA-EDTA Registry the unknown primary renal disease
appears as a diagnosis in 17% of the new cases in 1995, a
figure that remains quite uniform over the years.
It is evident that if clinical diagnosis is very rigorous,
many patients with possible renal vascular disease may
appear as having an unknown cause in a registry, while if
the clinical diagnosis is less rigorous, the percentage of
patients with unknown diagnosis is much lower. Curiously,
if the percentage of patients in the USRDS with renal
vascular disease (28.5%) is added to those with an un-
known diagnosis, a 32.9% figure is obtained, similar to that
of the ERA-EDTA Registry when adding the percentage of
new patients with renal vascular disease (13%) and un-
known diagnosis (17%), that is, 30%. This aspect must be
Fig. 1. (A) Incidence of renal vascular disease
in male patients starting renal replacement
therapy from 1976 to 1995 in the ERA-EDTA
Registry. (B) The same data in female patients.
Each block represents the year initiating RRT
that is 1977, 1981, 1985, 1989, 1993 and 1995,
respectively, left to right.
Fig. 2. Incidence of renal vascular disease as cause of ESRD in different
national registries. U.S. data are from the USRDS; European and
Spanish data from the ERA-EDTA Registry; Japanese data from the
Japanese Registry. *1991–1995; **1994.
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taken into account in future studies analyzing the possible
differences in the incidence of renal vascular disease.
In the future, it will be very important to reach an
agreement between the different international registries
and establish the diagnostic criteria for the different pri-
mary renal diseases, especially regarding hypertension.
Under these circumstances, it will be possible to learn
whether these differences really exist.
With regards to the prevalence of renal vascular disease
in patients on RRT in the ERA-EDTA Registry, 8% of the
stock of patients on RRT in 1995 had renal vascular disease
as primary renal disease (9% in Spain). In comparison, in
the USRDS, 24% of patients undergoing treatment from
1991 to 1993 were diagnosed with hypertension as cause of
ESRD.
SURVIVAL OF PATIENTS WITH RENAL VASCULAR
DISEASE ON RRT
Figure 3A shows the survival rates of patients with renal
vascular disease as the primary renal disease when starting
Fig. 3. (A) Survival of patients diagnosed with renal vascular disease on renal replacement therapy. All ages of patients of both sexes are included.
The survival of four different cohorts of patients is analyzed: patients starting RRT in 1977 (N 5 781), 1981 (N 5 1352), 1985 (N 5 2016) and 1989
(N 5 2849). Data are from the ERA-EDTA Registry. (B) The same data from patients diagnosed with standard renal disease. All ages and patients
of both sexes are included. The survival of four different cohorts of patients is analyzed: patients starting RRT in 1977 (N 5 9245), 1981 (N 5 13193),
1985 (N 5 16702) and 1989 (N 5 20012).
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RRT in 1977, 1981, 1985 and 1989. There is no improve-
ment in survival observed during these years, however,
there was a slight worsening of survival in the group of
patients starting treatment in the most recent year (1989).
All patients of all ages and both sexes are included in this
analysis.
The ERA-EDTA Registry has frequently used the con-
cept of standard primary renal disease as a comparative
model in multiple analyses. Included in the definition of
standard primary renal disease are all patients with primi-
tive non-secondary nephropathies. Therefore, this concept
groups all types of glomerulonephritis, pyelonephritis and
interstitial nephritis, toxic and drug induced nephropathies
and cystic diseases.
Figure 3B shows the survival of patients diagnosed with
standard primary renal disease of both sexes and all ages
who started RRT during the same years (1977, 1981, 1985
and 1989). Actuarial survival observed did not improve in
Fig. 4. (A) Survival of patients diagnosed with renal vascular disease on renal replacement therapy. Only patients younger than 55 of both sexes are
included. The survival of four different cohorts of patients is analyzed: patients starting RRT in 1977 (N 5 482), 1981 (N 5 670), 1985 (N 5 702) and
1989 (N 5 791). (B) Survival of patients diagnosed with standard renal disease on renal replacement therapy. Only patients younger than 55 of both
sexes are included. The survival of four different cohorts of patients is analyzed: patients starting RRT in 1977 (N 5 6664), 1981 (N 5 8420), 1985 (N 5
9535) and 1989 (N 5 10456).
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the years analyzed, and remained stable, but is nearly 20%
lower at 5 and 10 years in patients with renal vascular
disease compared to patients with standard renal disease.
This could give the impression that the results of RRT
have not improved over the past decades, but we must take
into account that, simultaneously in the years studied, there
has been a significant increase in the age of new patients. In
effect, in 1977 only 9.5% of all patients starting RRT were
over 65. In 1987, 25% were over 65 and in 1992, 38% were
over this age [2]. Therefore, when we evaluate survival
results, we must take into account that the populations
analyzed have varied fundamentally in age and, in effect,
when we study a more uniform population, that of patients
under 55 starting RRT in 1977, 1981, 1985 and 1989, we can
see an improvement both in patients with renal vascular
disease (Fig. 4A) and in patients with standard renal
disease (Fig. 4B). In each patient population analyzed at
the four year difference in time in which they started RRT,
actuarial survival is comparatively better than that of the
preceding years. In the group of patients under 55 we again
observe that survival is worse for patients with renal
vascular disease. When we compare survival at 5 and 10
years of the patients starting treatment in 1985 of all ages or
under 55, we see better survival rates at 5 and 10 years in
those under 55 with standard primary renal disease. This is
lower for the same group in cases of renal vascular disease.
CAUSES OF DEATH IN PATIENTS ON RRT
We selected a uniform population, that of patients
reported dead to the ERA-EDTA Registry in 1993. In that
year, a total of 8,890 patients with a diagnosis of standard
primary renal disease and 1,959 patients with renal vascular
disease died. When we analyze the percentages of the
different causes of death in these cases (Fig. 5), it is most
interesting to note that cardiac causes were responsible for
death in 42% of the patients with renal vascular disease as
compared to 37% of the patients with standard primary
renal disease. There is no difference in the other causes of
death, with the exception of infections, which show a
slightly lower percentage in patients diagnosed with renal
vascular disease than in those diagnosed with standard
primary renal disease.
This finding is in alignment with the existence of lesser
survival in patients with renal vascular disease. The prob-
ability of the existence of cardiopathies in these patients is
higher and has more repercussions than in patients with
standard primary disease.
CONCLUSIONS
In Europe, the incidence of hypertension as a cause of
ESRD has doubled (7% to 13%) in the last two decades, in
Fig. 5. Percentage of different causes of death in renal replacement therapy patients diagnosed with renal vascular disease and with standard renal
disease. Data are the patients reported dead in 1993 to the ERA EDTA Registry. Abbreviations are: CARD, cardiac; VASC, vascular; INF, infections;
UNK, unknown; SOC, social (suicide and discontinuation of treatment). Those with renal vascular disease numbered 1959, and those with standard
renal disease numbered 8890.
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parallel to the increase in age of new patients. Geograph-
ical differences do exist, ranging from an incidence of 6% in
Japan to 28.5% in the U.S., however, the diagnosis criteria
are not uniform. Concensus among different national reg-
istries of renal patients is necessary to standardize clear
diagnosis parameters of nephrosclerosis and ischemic ne-
phropathy before national registry data can be validly
compared.
Five and ten year survival rates of patients with renal
vascular disease is worse than that of patients with standard
renal disease. Neither of these survival rates has improved
in the last decade. However, survival of patients under 55
has improved in those starting RRT in the 80s, compared to
that of patients starting RRT in the 70s. Nevertheless,
survival of patients under 55 with renal vascular disease
remains worse than that of patients with standard renal
disease. The worse survival of patients with renal vascular
disease could be related to a higher cardiac mortality in this
group of patients.
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